Six months after his controversial departure from the top spot at the FDA’s biologics division, Peter Marks has landed at Eli Lilly, joining former colleague Rachael Anatol, who was ousted from the agency not long after Marks.
Marks Finds His Next Role as Lilly Snags Another Former FDA Regulator Read More »
Six takeaways from the CMS administrator’s appearance at a D.C. think tank Monday — including who’s set to be the next Medicaid director.
Oz speaks out about shutdown, Medicaid cuts, Medicare Advantage audits and more Read More »
CEOs for the systems called the outcome disappointing and did not suggest there would be future plans to merge.
Capacity at the company’s Boston site will increase by 50% as part of a $600 million, 10-year commitment to the U.S.
Convatec plans $1B investment in R&D in the US and UK Read More »
The deal gives the customer experience firm access to Press Ganey’s extensive healthcare data to bolster artificial intelligence capabilities.
Qualtrics to acquire healthcare market research firm Press Ganey for $6.75B Read More »
The plaintiffs argue that speech in certain healthcare settings ought to be protected by the First Amendment. Critics say that sets a dangerous precedent, where providers can offer debunked or harmful medical advice with impunity.
Supreme Court hears challenge to Colorado’s ban on conversion therapy Read More »
MedSec CEO Michelle Jump spoke with MedTech Dive at AdvaMed’s annual meeting about the FDA’s shift from a “carrot” to a “stick” approach in cybersecurity regulation.
How the FDA’s crackdown on cybersecurity affects medtech firms Read More »
At AdvaMed’s The MedTech Conference, executives said they’re incorporating AI in more devices, but figuring out how to use the technology internally is more challenging.
Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction from the current wholesale acquisition cost of $527.70.
Amgen Hops on DTC Train To Offer Repatha at 60% Discount Read More »
Skye Bioscience’s nimacimab fell short of investor and company expectations, but showed encouraging weight-loss results when combined with Wegovy, according to analysts at William Blair.
